FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3133669355> ?p ?o ?g. }

• W3133669355 endingPage "711" @default.
• W3133669355 startingPage "699" @default.
• W3133669355 abstract "BackgroundStudies of patients admitted to hospital with COVID-19 have found varying mortality outcomes associated with underlying respiratory conditions and inhaled corticosteroid use. Using data from a national, multicentre, prospective cohort, we aimed to characterise people with COVID-19 admitted to hospital with underlying respiratory disease, assess the level of care received, measure in-hospital mortality, and examine the effect of inhaled corticosteroid use.MethodsWe analysed data from the International Severe Acute Respiratory and emerging Infection Consortium (ISARIC) WHO Clinical Characterisation Protocol UK (CCP-UK) study. All patients admitted to hospital with COVID-19 across England, Scotland, and Wales between Jan 17 and Aug 3, 2020, were eligible for inclusion in this analysis. Patients with asthma, chronic pulmonary disease, or both, were identified and stratified by age (<16 years, 16–49 years, and ≥50 years). In-hospital mortality was measured by use of multilevel Cox proportional hazards, adjusting for demographics, comorbidities, and medications (inhaled corticosteroids, short-acting β-agonists [SABAs], and long-acting β-agonists [LABAs]). Patients with asthma who were taking an inhaled corticosteroid plus LABA plus another maintenance asthma medication were considered to have severe asthma.Findings75 463 patients from 258 participating health-care facilities were included in this analysis: 860 patients younger than 16 years (74 [8·6%] with asthma), 8950 patients aged 16–49 years (1867 [20·9%] with asthma), and 65 653 patients aged 50 years and older (5918 [9·0%] with asthma, 10 266 [15·6%] with chronic pulmonary disease, and 2071 [3·2%] with both asthma and chronic pulmonary disease). Patients with asthma were significantly more likely than those without asthma to receive critical care (patients aged 16–49 years: adjusted odds ratio [OR] 1·20 [95% CI 1·05–1·37]; p=0·0080; patients aged ≥50 years: adjusted OR 1·17 [1·08–1·27]; p<0·0001), and patients aged 50 years and older with chronic pulmonary disease (with or without asthma) were significantly less likely than those without a respiratory condition to receive critical care (adjusted OR 0·66 [0·60–0·72] for those without asthma and 0·74 [0·62–0·87] for those with asthma; p<0·0001 for both). In patients aged 16–49 years, only those with severe asthma had a significant increase in mortality compared to those with no asthma (adjusted hazard ratio [HR] 1·17 [95% CI 0·73–1·86] for those on no asthma therapy, 0·99 [0·61–1·58] for those on SABAs only, 0·94 [0·62–1·43] for those on inhaled corticosteroids only, 1·02 [0·67–1·54] for those on inhaled corticosteroids plus LABAs, and 1·96 [1·25–3·08] for those with severe asthma). Among patients aged 50 years and older, those with chronic pulmonary disease had a significantly increased mortality risk, regardless of inhaled corticosteroid use, compared to patients without an underlying respiratory condition (adjusted HR 1·16 [95% CI 1·12–1·22] for those not on inhaled corticosteroids, and 1·10 [1·04–1·16] for those on inhaled corticosteroids; p<0·0001). Patients aged 50 years and older with severe asthma also had an increased mortality risk compared to those not on asthma therapy (adjusted HR 1·24 [95% CI 1·04–1·49]). In patients aged 50 years and older, inhaled corticosteroid use within 2 weeks of hospital admission was associated with decreased mortality in those with asthma, compared to those without an underlying respiratory condition (adjusted HR 0·86 [95% CI 0·80−0·92]).InterpretationUnderlying respiratory conditions are common in patients admitted to hospital with COVID-19. Regardless of the severity of symptoms at admission and comorbidities, patients with asthma were more likely, and those with chronic pulmonary disease less likely, to receive critical care than patients without an underlying respiratory condition. In patients aged 16 years and older, severe asthma was associated with increased mortality compared to non-severe asthma. In patients aged 50 years and older, inhaled corticosteroid use in those with asthma was associated with lower mortality than in patients without an underlying respiratory condition; patients with chronic pulmonary disease had significantly increased mortality compared to those with no underlying respiratory condition, regardless of inhaled corticosteroid use. Our results suggest that the use of inhaled corticosteroids, within 2 weeks of admission, improves survival for patients aged 50 years and older with asthma, but not for those with chronic pulmonary disease.FundingNational Institute for Health Research, Medical Research Council, NIHR Health Protection Research Units in Emerging and Zoonotic Infections at the University of Liverpool and in Respiratory Infections at Imperial College London in partnership with Public Health England." @default.
• W3133669355 created "2021-03-15" @default.
• W3133669355 creator A5000064307 @default.
• W3133669355 creator A5000184140 @default.
• W3133669355 creator A5000781338 @default.
• W3133669355 creator A5001065613 @default.
• W3133669355 creator A5001844277 @default.
• W3133669355 creator A5001964954 @default.
• W3133669355 creator A5002068509 @default.
• W3133669355 creator A5002152360 @default.
• W3133669355 creator A5002494349 @default.
• W3133669355 creator A5002766306 @default.
• W3133669355 creator A5002884413 @default.
• W3133669355 creator A5003035350 @default.
• W3133669355 creator A5003057228 @default.
• W3133669355 creator A5003141508 @default.
• W3133669355 creator A5003265180 @default.
• W3133669355 creator A5003380716 @default.
• W3133669355 creator A5003474421 @default.
• W3133669355 creator A5004536030 @default.
• W3133669355 creator A5005387077 @default.
• W3133669355 creator A5005390531 @default.
• W3133669355 creator A5005828261 @default.
• W3133669355 creator A5005961505 @default.
• W3133669355 creator A5006379970 @default.
• W3133669355 creator A5006608288 @default.
• W3133669355 creator A5006895135 @default.
• W3133669355 creator A5007089595 @default.
• W3133669355 creator A5007128781 @default.
• W3133669355 creator A5007600157 @default.
• W3133669355 creator A5008389051 @default.
• W3133669355 creator A5008592726 @default.
• W3133669355 creator A5009181483 @default.
• W3133669355 creator A5009424408 @default.
• W3133669355 creator A5009577840 @default.
• W3133669355 creator A5009617051 @default.
• W3133669355 creator A5009876664 @default.
• W3133669355 creator A5010398686 @default.
• W3133669355 creator A5010417984 @default.
• W3133669355 creator A5010604010 @default.
• W3133669355 creator A5011455207 @default.
• W3133669355 creator A5011680834 @default.
• W3133669355 creator A5012124186 @default.
• W3133669355 creator A5012130512 @default.
• W3133669355 creator A5012228981 @default.
• W3133669355 creator A5013194012 @default.
• W3133669355 creator A5013371192 @default.
• W3133669355 creator A5013705456 @default.
• W3133669355 creator A5013768166 @default.
• W3133669355 creator A5013792340 @default.
• W3133669355 creator A5013988094 @default.
• W3133669355 creator A5014104089 @default.
• W3133669355 creator A5014167419 @default.
• W3133669355 creator A5014257962 @default.
• W3133669355 creator A5014273331 @default.
• W3133669355 creator A5014380172 @default.
• W3133669355 creator A5014502334 @default.
• W3133669355 creator A5014687287 @default.
• W3133669355 creator A5014753400 @default.
• W3133669355 creator A5014756420 @default.
• W3133669355 creator A5014774953 @default.
• W3133669355 creator A5015120901 @default.
• W3133669355 creator A5015295034 @default.
• W3133669355 creator A5015402059 @default.
• W3133669355 creator A5015508529 @default.
• W3133669355 creator A5015937002 @default.
• W3133669355 creator A5016924847 @default.
• W3133669355 creator A5017281345 @default.
• W3133669355 creator A5018202193 @default.
• W3133669355 creator A5018627748 @default.
• W3133669355 creator A5018746550 @default.
• W3133669355 creator A5018758025 @default.
• W3133669355 creator A5018937505 @default.
• W3133669355 creator A5019272887 @default.
• W3133669355 creator A5019818200 @default.
• W3133669355 creator A5019903779 @default.
• W3133669355 creator A5020079265 @default.
• W3133669355 creator A5020173124 @default.
• W3133669355 creator A5020345893 @default.
• W3133669355 creator A5020767468 @default.
• W3133669355 creator A5021183367 @default.
• W3133669355 creator A5021468463 @default.
• W3133669355 creator A5021538869 @default.
• W3133669355 creator A5021567967 @default.
• W3133669355 creator A5021680442 @default.
• W3133669355 creator A5021752244 @default.
• W3133669355 creator A5023098195 @default.
• W3133669355 creator A5023171939 @default.
• W3133669355 creator A5023187913 @default.
• W3133669355 creator A5023940756 @default.
• W3133669355 creator A5024246999 @default.
• W3133669355 creator A5024685232 @default.
• W3133669355 creator A5024985443 @default.
• W3133669355 creator A5025315199 @default.
• W3133669355 creator A5025511065 @default.
• W3133669355 creator A5025518421 @default.
• W3133669355 creator A5026183673 @default.
• W3133669355 creator A5026548802 @default.

• next